NitroMed BiDil Heart Failure Indication For African Americans To Be Reviewed By Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will meet June 16 to consider the resubmitted BiDil NDA. Drug could be first approval specifically for African Americans. Committee will also meet June 15 to discuss antihypertensive class labeling.
You may also be interested in...
NitroMed BiDil Recommended For Heart Failure In Self-Identified African-Americans
Indication to treat heart failure in the general population is discussed, but rejected, by FDA’s Cardiovascular & Renal Drugs Advisory Committee. Despite mortality benefit seen in A-HeFT, some committee members call strength of evidence a “close call.”
NitroMed BiDil Recommended For Heart Failure In Self-Identified African-Americans
Indication to treat heart failure in the general population is discussed, but rejected, by FDA’s Cardiovascular & Renal Drugs Advisory Committee. Despite mortality benefit seen in A-HeFT, some committee members call strength of evidence a “close call.”
FDA Proposes Antihypertensive Class Indication For Reducing CV Events
Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.